Helicobacter pylori infection and nonalcoholic fatty liver disease: are the four meta-analyses favoring an intriguing association pointing to the right direction?
Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance (IR) and the metabolic syndrome (MetS) and is a leading cause of cirrhosis [1,2]. Its global prevalence is 25% [3] and is increasing worldwide [4] accompanied by severe complications particularly in high-risk older obese patients [5]. Thiazolidinediones, statins and vitamin E have been proposed for the management of NAFLD [6,7] together with lifestyle modifications [8], but there is currently no specifically approved medication.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros Source Type: research
More News: Biomedical Science | Cholesterol | Cirrhosis | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Helicobacter Pylori | Insulin | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Statin Therapy | Urology & Nephrology | Vitamin E | Vitamins